Does the media prefer INDV or INBX?

In the previous week, Indivior had 2 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 4 mentions for Indivior and 2 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 0.97 beat Indivior's score of 0.22 indicating that Inhibrx Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indivior 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Inhibrx Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is INBX or MANE more profitable?

Veradermics' return on equity of 0.00% beat Inhibrx Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Inhibrx Biosciences N/A -563.90% -72.32% Veradermics N/A N/A N/A

Does the media refer more to INBX or MANE?

In the previous week, Veradermics had 4 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 6 mentions for Veradermics and 2 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 0.97 beat Veradermics' score of -0.14 indicating that Inhibrx Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibrx Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veradermics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer INBX or CRSP?

In the previous week, CRISPR Therapeutics had 9 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 11 mentions for CRISPR Therapeutics and 2 mentions for Inhibrx Biosciences. CRISPR Therapeutics' average media sentiment score of 1.03 beat Inhibrx Biosciences' score of 0.97 indicating that CRISPR Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibrx Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CRISPR Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor LEGN or INBX?

In the previous week, Legend Biotech had 2 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 4 mentions for Legend Biotech and 2 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 0.97 beat Legend Biotech's score of 0.81 indicating that Inhibrx Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inhibrx Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Inhibrx Biosciences (INBX) Competitors

$81.55 0.00 (0.00%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$82.24 +0.70 (+0.85%)

As of 07/24/2026 07:34 PM Eastern

Compare

INBX vs. KNSA, INDV, MANE, CRSP, and LEGN

Should you buy Inhibrx Biosciences stock or one of its competitors? MarketBeat compares Inhibrx Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Inhibrx Biosciences include Kiniksa Pharmaceuticals International (KNSA), Indivior (INDV), Veradermics (MANE), CRISPR Therapeutics (CRSP), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry.

How does Inhibrx Biosciences compare to Kiniksa Pharmaceuticals International?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Inhibrx Biosciences (NASDAQ:INBX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

In the previous week, Kiniksa Pharmaceuticals International had 7 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 9 mentions for Kiniksa Pharmaceuticals International and 2 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 0.97 beat Kiniksa Pharmaceuticals International's score of 0.66 indicating that Inhibrx Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kiniksa Pharmaceuticals International	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inhibrx Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kiniksa Pharmaceuticals International has higher revenue and earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiniksa Pharmaceuticals International	$677.56M	7.14	$59.01M	$0.90	69.82
Inhibrx Biosciences	$1.30M	920.26	-$140.05M	-$8.39	N/A

Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to Inhibrx Biosciences' net margin of 0.00%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%
Inhibrx Biosciences	N/A	-563.90%	-72.32%

Kiniksa Pharmaceuticals International has a beta of 0.07, meaning that its stock price is 93% less volatile than the broader market. Comparatively, Inhibrx Biosciences has a beta of 3.41, meaning that its stock price is 241% more volatile than the broader market.

54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are owned by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are owned by insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Kiniksa Pharmaceuticals International presently has a consensus target price of $68.00, indicating a potential upside of 8.21%. Inhibrx Biosciences has a consensus target price of $150.00, indicating a potential upside of 83.94%. Given Inhibrx Biosciences' higher probable upside, analysts clearly believe Inhibrx Biosciences is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiniksa Pharmaceuticals International	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33

Summary

Kiniksa Pharmaceuticals International beats Inhibrx Biosciences on 11 of the 16 factors compared between the two stocks.

How does Inhibrx Biosciences compare to Indivior?

Indivior (NASDAQ:INDV) and Inhibrx Biosciences (NASDAQ:INBX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

Indivior has higher revenue and earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$1.24B	3.99	$210M	$1.95	20.78
Inhibrx Biosciences	$1.30M	920.26	-$140.05M	-$8.39	N/A

In the previous week, Indivior had 2 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 4 mentions for Indivior and 2 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 0.97 beat Indivior's score of 0.22 indicating that Inhibrx Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indivior	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inhibrx Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Indivior presently has a consensus price target of $43.67, indicating a potential upside of 7.74%. Inhibrx Biosciences has a consensus price target of $150.00, indicating a potential upside of 83.94%. Given Inhibrx Biosciences' higher probable upside, analysts plainly believe Inhibrx Biosciences is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33

Indivior has a net margin of 19.44% compared to Inhibrx Biosciences' net margin of 0.00%. Indivior's return on equity of -219.26% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indivior	19.44%	-219.26%	29.40%
Inhibrx Biosciences	N/A	-563.90%	-72.32%

Indivior has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, Inhibrx Biosciences has a beta of 3.41, indicating that its stock price is 241% more volatile than the broader market.

60.3% of Indivior shares are owned by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are owned by institutional investors. 0.7% of Indivior shares are owned by insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Indivior beats Inhibrx Biosciences on 10 of the 17 factors compared between the two stocks.

How does Inhibrx Biosciences compare to Veradermics?

Inhibrx Biosciences (NASDAQ:INBX) and Veradermics (NYSE:MANE) are both pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

82.5% of Inhibrx Biosciences shares are owned by institutional investors. 18.3% of Inhibrx Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Inhibrx Biosciences currently has a consensus target price of $150.00, indicating a potential upside of 83.94%. Veradermics has a consensus target price of $153.00, indicating a potential upside of 39.32%. Given Inhibrx Biosciences' higher possible upside, analysts plainly believe Inhibrx Biosciences is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Veradermics has lower revenue, but higher earnings than Inhibrx Biosciences. Veradermics is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx Biosciences	$1.30M	920.26	-$140.05M	-$8.39	N/A
Veradermics	N/A	N/A	N/A	-$1.32	N/A

Veradermics' return on equity of 0.00% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibrx Biosciences	N/A	-563.90%	-72.32%
Veradermics	N/A	N/A	N/A

In the previous week, Veradermics had 4 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 6 mentions for Veradermics and 2 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 0.97 beat Veradermics' score of -0.14 indicating that Inhibrx Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibrx Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veradermics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Inhibrx Biosciences beats Veradermics on 7 of the 13 factors compared between the two stocks.

How does Inhibrx Biosciences compare to CRISPR Therapeutics?

Inhibrx Biosciences (NASDAQ:INBX) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership.

Inhibrx Biosciences has higher earnings, but lower revenue than CRISPR Therapeutics. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx Biosciences	$1.30M	920.26	-$140.05M	-$8.39	N/A
CRISPR Therapeutics	$3.51M	1,278.86	-$581.60M	-$6.22	N/A

Inhibrx Biosciences has a beta of 3.41, indicating that its share price is 241% more volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.71, indicating that its share price is 71% more volatile than the broader market.

Inhibrx Biosciences has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibrx Biosciences	N/A	-563.90%	-72.32%
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%

Inhibrx Biosciences presently has a consensus target price of $150.00, indicating a potential upside of 83.94%. CRISPR Therapeutics has a consensus target price of $67.78, indicating a potential upside of 45.63%. Given Inhibrx Biosciences' higher probable upside, equities research analysts clearly believe Inhibrx Biosciences is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58

In the previous week, CRISPR Therapeutics had 9 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 11 mentions for CRISPR Therapeutics and 2 mentions for Inhibrx Biosciences. CRISPR Therapeutics' average media sentiment score of 1.03 beat Inhibrx Biosciences' score of 0.97 indicating that CRISPR Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibrx Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CRISPR Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

82.5% of Inhibrx Biosciences shares are held by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are held by institutional investors. 18.3% of Inhibrx Biosciences shares are held by insiders. Comparatively, 5.2% of CRISPR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

CRISPR Therapeutics beats Inhibrx Biosciences on 10 of the 16 factors compared between the two stocks.

How does Inhibrx Biosciences compare to Legend Biotech?

Legend Biotech (NASDAQ:LEGN) and Inhibrx Biosciences (NASDAQ:INBX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

Inhibrx Biosciences has lower revenue, but higher earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.03B	4.01	-$296.80M	-$0.68	N/A
Inhibrx Biosciences	$1.30M	920.26	-$140.05M	-$8.39	N/A

Legend Biotech has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market. Comparatively, Inhibrx Biosciences has a beta of 3.41, suggesting that its stock price is 241% more volatile than the broader market.

Inhibrx Biosciences has a net margin of 0.00% compared to Legend Biotech's net margin of -21.98%. Legend Biotech's return on equity of -24.92% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-21.98%	-24.92%	-14.87%
Inhibrx Biosciences	N/A	-563.90%	-72.32%

Legend Biotech currently has a consensus price target of $55.38, suggesting a potential upside of 149.26%. Inhibrx Biosciences has a consensus price target of $150.00, suggesting a potential upside of 83.94%. Given Legend Biotech's stronger consensus rating and higher possible upside, equities research analysts clearly believe Legend Biotech is more favorable than Inhibrx Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33

In the previous week, Legend Biotech had 2 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 4 mentions for Legend Biotech and 2 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 0.97 beat Legend Biotech's score of 0.81 indicating that Inhibrx Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Legend Biotech	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inhibrx Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

70.9% of Legend Biotech shares are owned by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are owned by institutional investors. 0.0% of Legend Biotech shares are owned by insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Inhibrx Biosciences beats Legend Biotech on 9 of the 17 factors compared between the two stocks.

Get Inhibrx Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INBX vs. The Competition

Export

Metric	Inhibrx Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.20B	$3.66B	$6.90B	$12.20B
Dividend Yield	N/A	2.18%	2.67%	9.80%
P/E Ratio	-9.72	21.48	27.16	23.63
Price / Sales	920.26	298.31	521.43	88.64
Price / Cash	N/A	59.51	26.39	46.67
Price / Book	148.27	7.89	10.28	6.08
Net Income	-$140.05M	$23.81M	$3.60B	$331.70M
7 Day Performance	-3.02%	-2.39%	-0.28%	-0.05%
1 Month Performance	-13.99%	-4.47%	-1.76%	-2.63%
1 Year Performance	253.34%	33.01%	18.25%	13.91%

Inhibrx Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INBX Inhibrx Biosciences	2.669 of 5 stars	$81.55 flat	$150.00 +83.9%	+253.3%	$1.20B	$1.30M	N/A	166
KNSA Kiniksa Pharmaceuticals International	2.928 of 5 stars	$63.55 +1.6%	$65.14 +2.5%	+138.7%	$4.81B	$677.56M	70.61	220	Upcoming Earnings
INDV Indivior	2.2967 of 5 stars	$40.45 +3.4%	$40.29 -0.4%	+136.5%	$4.77B	$1.24B	20.74	1,051	Upcoming Earnings Analyst Upgrade
MANE Veradermics	2.4005 of 5 stars	$109.19 +3.0%	$153.00 +40.1%	N/A	$4.56B	N/A	N/A	19
CRSP CRISPR Therapeutics	3.5608 of 5 stars	$48.15 +2.5%	$67.78 +40.8%	-28.1%	$4.53B	$3.51M	N/A	460	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INBX) was last updated on 7/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Inhibrx Biosciences (INBX) Competitors

INBX vs. KNSA, INDV, MANE, CRSP, and LEGN

How does Inhibrx Biosciences compare to Kiniksa Pharmaceuticals International?

Summary

How does Inhibrx Biosciences compare to Indivior?

Summary

How does Inhibrx Biosciences compare to Veradermics?

Summary

How does Inhibrx Biosciences compare to CRISPR Therapeutics?

Summary

How does Inhibrx Biosciences compare to Legend Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INBX vs. The Competition

Inhibrx Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Inhibrx Biosciences (INBX) Competitors

INBX vs. KNSA, INDV, MANE, CRSP, and LEGN

How does Inhibrx Biosciences compare to Kiniksa Pharmaceuticals International?

Does the media favor KNSA or INBX?

Which has higher valuation and earnings, KNSA or INBX?

Is KNSA or INBX more profitable?

Which has more risk & volatility, KNSA or INBX?

Do insiders & institutionals have more ownership in KNSA or INBX?

Do analysts rate KNSA or INBX?

Summary

How does Inhibrx Biosciences compare to Indivior?

Which has higher valuation & earnings, INDV or INBX?

Does the media prefer INDV or INBX?

Do analysts rate INDV or INBX?

Is INDV or INBX more profitable?

Which has more risk & volatility, INDV or INBX?

Do insiders & institutionals believe in INDV or INBX?

Summary

How does Inhibrx Biosciences compare to Veradermics?

Do institutionals and insiders believe in INBX or MANE?

Do analysts recommend INBX or MANE?

Which has stronger earnings and valuation, INBX or MANE?

Is INBX or MANE more profitable?

Does the media refer more to INBX or MANE?

Summary

How does Inhibrx Biosciences compare to CRISPR Therapeutics?

Which has stronger earnings & valuation, INBX or CRSP?

Which has more volatility & risk, INBX or CRSP?

Is INBX or CRSP more profitable?

Do analysts rate INBX or CRSP?

Does the media prefer INBX or CRSP?

Do institutionals & insiders hold more shares of INBX or CRSP?

Summary

How does Inhibrx Biosciences compare to Legend Biotech?

Which has better valuation & earnings, LEGN or INBX?

Which has more risk and volatility, LEGN or INBX?

Is LEGN or INBX more profitable?

Do analysts rate LEGN or INBX?

Does the media favor LEGN or INBX?

Do insiders and institutionals hold more shares of LEGN or INBX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INBX vs. The Competition

Inhibrx Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools